The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients
Recruiting · NCT06998745 · Interventional (participants receive a specific treatment) · Lead sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
View the official record on ClinicalTrials.gov →Interventions studied
Medication Therapy Management (MTM) model
What this trial is about
Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high probability of recurrent VTE and bleeding during anticoagulation therapy.The Medication Therapy Management (MTM) model will contribute to reducing ADEs associated with anticoagulants in CRC patients.
Who can take part
Age range
18 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.
- CRC patients with VTE treated with an anticoagulant for at least 3 moths.
Exclusion criteria
- Participation in this study required active anticoagulant treatment. Apart from this, there were no specific exclusion criteria.
Where it is running
1 location listed.
- Sixth Affiliated Hospital, Sun Yat-sen University - Guangzhou, Guangdong, China